American Journal Of Cardiovascular Drugs

SCIE

國際簡稱：AM J CARDIOVASC DRUG 參考譯名：美國心血管藥物雜志

主要研究方向：醫學-心血管系統非預警期刊審稿周期： 12周，或約稿

《美國心血管藥物雜志》(American Journal Of Cardiovascular Drugs)是一本由Springer International Publishing出版的以醫學-心血管系統為研究特色的國際期刊，發表該領域相關的原創研究文章、評論文章和綜述文章，及時報道該領域相關理論、實踐和應用學科的最新發現，旨在促進該學科領域科學信息的快速交流。該期刊是一本未開放期刊，近三年沒有被列入預警名單。

4區中科院分區
Q2 JCR分區
56 年發文量
2.8 IF影響因子
未開放 是否OA
46 H-index
2001 創刊年份
Bimonthly 出版周期
English 出版語言

Promoting rational therapy within the discipline of cardiology, the American Journal of Cardiovascular Drugs covers all aspects of the treatment of cardiovascular disorders, particularly the place in therapy of newer and established agents.

Via a program of reviews and original clinical research articles, the journal addresses major issues relating to treatment of these disorders, including the pharmacology, efficacy and adverse effects of the major classes of drugs; information on newly developed drugs and drug classes; the therapeutic implications of latest research into the aetiology of cardiovascular disorders; and the practical management of specific clinical situations.

The American Journal of Cardiovascular Drugs offers a range of additional enhanced features designed to increase the visibility, readership and educational value of the journal’s content. Each article is accompanied by a Key Points summary, giving a time-efficient overview of the content to a wide readership. Articles may be accompanied by plain language summaries to assist patients, caregivers and others in understanding important medical advances. The journal also provides the option to include various other types of enhanced features including slide sets, videos and animations. All enhanced features are peer reviewed to the same high standard as the article itself. Peer review is conducted using Editorial Manager?, supported by a database of international experts. This database is shared with other Adis journals.

[ 查看全部 ]

投稿咨詢加急咨詢

American Journal Of Cardiovascular Drugs期刊信息

ISSN：1175-3277
出版語言：English
是否OA：未開放
E-ISSN：1179-187X
出版地區：NEW ZEALAND
是否預警：否
出版商：Springer International Publishing
出版周期：Bimonthly
創刊時間：2001
開源占比：0.2011
Gold OA文章占比：29.66%
OA被引用占比：0.2597...
出版國人文章占比：0.12
出版撤稿占比：0
研究類文章占比：51.79%

American Journal Of Cardiovascular Drugs CiteScore評價數據（2024年最新版）

CiteScore

SJR

SNIP

CiteScore 指數

6.7

0.79

0.784

學科類別	分區	排名	百分位
大類：Medicine 小類：Cardiology and Cardiovascular Medicine	Q1	74 / 387	81%
大類：Medicine 小類：Pharmacology (medical)	Q1	63 / 272	77%

名詞解釋：CiteScore 是衡量期刊所發表文獻的平均受引用次數，是在 Scopus 中衡量期刊影響力的另一個指標。當年CiteScore 的計算依據是期刊最近4年（含計算年度）的被引次數除以該期刊近四年發表的文獻數。例如，2022年的 CiteScore 計算方法為：2022年的 CiteScore =2019-2022年收到的對2019-2022年發表的文件的引用數量÷2019-2022年發布的文獻數量注：文獻類型包括：文章、評論、會議論文、書籍章節和數據論文。

American Journal Of Cardiovascular Drugs中科院評價數據

中科院 2023年12月升級版

Top期刊	綜述期刊	大類學科		小類學科
否	否	醫學	4區	CARDIAC & CARDIOVASCULAR SYSTEMS 心臟和心血管系統 PHARMACOLOGY & PHARMACY 藥學	4區 4區

中科院 2022年12月升級版

Top期刊	綜述期刊	大類學科		小類學科
否	否	醫學	3區	CARDIAC & CARDIOVASCULAR SYSTEMS 心臟和心血管系統 PHARMACOLOGY & PHARMACY 藥學	3區 3區

中科院 2021年12月舊的升級版

Top期刊	綜述期刊	大類學科		小類學科
否	否	醫學	4區	PHARMACOLOGY & PHARMACY 藥學 CARDIAC & CARDIOVASCULAR SYSTEMS 心臟和心血管系統	3區 4區

中科院 2021年12月基礎版

Top期刊	綜述期刊	大類學科		小類學科
否	否	醫學	3區	CARDIAC & CARDIOVASCULAR SYSTEMS 心臟和心血管系統 PHARMACOLOGY & PHARMACY 藥學	4區 3區

中科院 2021年12月升級版

Top期刊	綜述期刊	大類學科		小類學科
否	否	醫學	4區	PHARMACOLOGY & PHARMACY 藥學 CARDIAC & CARDIOVASCULAR SYSTEMS 心臟和心血管系統	3區 4區

中科院 2020年12月舊的升級版

Top期刊	綜述期刊	大類學科		小類學科
否	否	醫學	4區	CARDIAC & CARDIOVASCULAR SYSTEMS 心臟和心血管系統 PHARMACOLOGY & PHARMACY 藥學	4區 4區

American Journal Of Cardiovascular Drugs JCR評價數據（2023-2024年最新版）

按JIF指標學科分區	收錄子集	分區	排名	百分位
學科：CARDIAC & CARDIOVASCULAR SYSTEMS	SCIE	Q2	79 / 220	64.3%
學科：PHARMACOLOGY & PHARMACY	SCIE	Q2	158 / 354	55.5%

按JCI指標學科分區	收錄子集	分區	排名	百分位
學科：CARDIAC & CARDIOVASCULAR SYSTEMS	SCIE	Q2	84 / 220	62.05%
學科：PHARMACOLOGY & PHARMACY	SCIE	Q2	163 / 354	54.1%

American Journal Of Cardiovascular Drugs歷年數據統計

影響因子

中科院分區

American Journal Of Cardiovascular Drugs中國學者發文選摘

1、Cost-Effectiveness of Adding Empagliflozin to Standard Treatment for Heart Failure with Preserved Ejection Fraction Patients in China
Author: Lou, Yake; Hu, Tianyang; Huang, Jing

Journal: AMERICAN JOURNAL OF CARDIOVASCULAR DRUGS. 2023; Vol. 23, Issue 1, pp. 47-57. DOI: 10.1007/s40256-022-00550-9
2、Antithrombotic Strategy in Secondary Prevention for High-Risk Patients with Previous Acute Coronary Syndrome: Overlap between the PEGASUS Eligibility and the COMPASS Eligibility in a Large Multicenter Registry
Author: Millesimo, Michele; Elia, Edoardo; Marengo, Giorgio; De Filippo, Ovidio; Raposeiras-Roubin, Sergio; Wanha, Wojciech; Abu-Assi, Emad; Kinnaird, Tim; Ariza-Sole, Albert; Liebetrau, Christoph; Manzano-Fernandez, Sergio; Iannaccone, Mario; Henriques, Jose Paulo Simao; Templin, Christian; Wilton, Stephen B.; Velicki, Lazar; Xanthopoulou, Ioanna; Correia, Luis; Cerrato, Enrico; Rognoni, Andrea; Nunez-Gil, Ivan; Song, Xiantao; Kawaji, Tetsuma; Quadri, Giorgio; Huczek, Zenon; Paz, Rafael Cobas; Juanatey, Jose Ramon Gonzalez; Nie, Shao-Ping; Kawashiri, Masa-Aki; Dominguez-Rodriguez, Alberto; Conrotto, Federico; D'Ascenzo, Fabrizio; De Ferrari, Gaetano Maria

Journal: AMERICAN JOURNAL OF CARDIOVASCULAR DRUGS. 2023; Vol. 23, Issue 1, pp. 77-87. DOI: 10.1007/s40256-022-00554-5
3、Safety and Tolerability of Tecarfarin (ATI-5923) in Healthy Chinese Volunteers: Multiple Oral Dose-Escalation Phase I Trial
Author: Zhou, Qiang; Wang, Zhiqiang; Wang, Heming; Chen, Zhidong; Li, Xiaoyi; Dai, Xiangrong; Zhang, Yong; Yu, Xiaohui; Zhou, Renpeng; Hu, Wei

Journal: AMERICAN JOURNAL OF CARDIOVASCULAR DRUGS. 2023; Vol. 23, Issue 1, pp. 101-112. DOI: 10.1007/s40256-022-00562-5
4、Endothelial-to-Mesenchymal Transition: Potential Target of Doxorubicin-Induced Cardiotoxicity
Author: Feng, Jie; Wu, Yanqing

Journal: AMERICAN JOURNAL OF CARDIOVASCULAR DRUGS. 2023; Vol. 23, Issue 3, pp. 231-246. DOI: 10.1007/s40256-023-00573-w
5、Prophylactic Efficacy and Safety of Antithrombotic Regimens in Patients with Stable Atherosclerotic Cardiovascular Disease (S-ASCVD): A Bayesian Network Meta-Regression Analysis
Author: Zheng, Nan; Zhong, Jinyan; Chen, Xi; Su, Jia; Liu, Chengjiang; Jiang, Longfu

Journal: AMERICAN JOURNAL OF CARDIOVASCULAR DRUGS. 2023; Vol. 23, Issue 3, pp. 257-267. DOI: 10.1007/s40256-023-00574-9
6、Characteristics and Trends in Clinical Trials of Cardiovascular Drugs in China from 2009 to 2021
Author: Hao, Jun; Li, Chen; Li, Junrong; Wang, Chuangshi; Li, Yang; He, Chen; Liu, Weida; Li, Sidong; Zuo, Ling; Hui, Wen

Journal: AMERICAN JOURNAL OF CARDIOVASCULAR DRUGS. 2023; Vol. 23, Issue 3, pp. 301-310. DOI: 10.1007/s40256-023-00575-8
7、Effects of Rosuvastatin and Aspirin on Retinal Vascular Structures in Hypercholesterolemic Patients with Low-to-Moderate Risk of Coronary Artery Disease
Author: Li Li, Shuang Wang, Huilian Huang, Yi Cai, Yutao Xi, Ying Bai, Changsheng Ma

Journal: American Journal of Cardiovascular Drugs, 2019, Vol., , DOI:10.1007/s40256-019-00330-y
8、The Efficacy and Safety of Aerosolized Iloprost in Pulmonary Arterial Hypertension: A Systematic Review and Meta-Analysis
Author: Hongyu Kuang, Qiang Li, Qijian Yi, Tiewei Lu

Journal: American Journal of Cardiovascular Drugs, 2019, Vol., , DOI:10.1007/s40256-018-00324-2